 Jason Hoppe
Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 39 | 2026 | 2383 | 4.480 |
Why?
| | Analgesics, Opioid | 24 | 2025 | 1154 | 4.240 |
Why?
| | Decision Support Systems, Clinical | 9 | 2025 | 273 | 3.680 |
Why?
| | Narcotic Antagonists | 12 | 2025 | 203 | 3.270 |
Why?
| | Buprenorphine | 9 | 2025 | 192 | 3.060 |
Why?
| | Prescription Drug Monitoring Programs | 6 | 2023 | 17 | 2.800 |
Why?
| | Opioid-Related Disorders | 12 | 2025 | 605 | 2.740 |
Why?
| | Naloxone | 4 | 2025 | 132 | 2.310 |
Why?
| | Practice Patterns, Physicians' | 16 | 2025 | 1372 | 2.140 |
Why?
| | Opiate Substitution Treatment | 8 | 2025 | 189 | 1.590 |
Why?
| | Drug Prescriptions | 6 | 2025 | 288 | 1.440 |
Why?
| | Alcoholism | 4 | 2026 | 826 | 1.390 |
Why?
| | Back Pain | 4 | 2023 | 52 | 1.270 |
Why?
| | Electronic Health Records | 7 | 2025 | 1202 | 1.100 |
Why?
| | Pain | 4 | 2023 | 791 | 0.990 |
Why?
| | Prescription Drugs | 5 | 2017 | 111 | 0.970 |
Why?
| | Naltrexone | 2 | 2025 | 115 | 0.880 |
Why?
| | Emergency Medicine | 3 | 2024 | 282 | 0.710 |
Why?
| | Drug Overdose | 5 | 2021 | 375 | 0.680 |
Why?
| | Length of Stay | 3 | 2024 | 1350 | 0.590 |
Why?
| | Retrospective Studies | 19 | 2026 | 17325 | 0.490 |
Why?
| | Humans | 55 | 2026 | 145763 | 0.490 |
Why?
| | Middle Aged | 21 | 2026 | 36302 | 0.480 |
Why?
| | Pain Management | 3 | 2017 | 411 | 0.480 |
Why?
| | Adult | 27 | 2025 | 40872 | 0.480 |
Why?
| | Attitude of Health Personnel | 4 | 2024 | 1197 | 0.470 |
Why?
| | Controlled Substances | 1 | 2014 | 2 | 0.430 |
Why?
| | Physicians | 3 | 2024 | 956 | 0.430 |
Why?
| | Male | 31 | 2026 | 73003 | 0.420 |
Why?
| | Pharmacies | 1 | 2014 | 40 | 0.410 |
Why?
| | Substance Abuse Detection | 2 | 2014 | 110 | 0.400 |
Why?
| | Drug Monitoring | 2 | 2017 | 401 | 0.400 |
Why?
| | Prescriptions | 2 | 2023 | 74 | 0.390 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.390 |
Why?
| | Female | 29 | 2026 | 79035 | 0.390 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2025 | 185 | 0.360 |
Why?
| | Cannabinoids | 3 | 2020 | 184 | 0.340 |
Why?
| | Pharmacists | 1 | 2014 | 258 | 0.340 |
Why?
| | Hospitalization | 3 | 2026 | 2460 | 0.300 |
Why?
| | Patient Discharge | 1 | 2016 | 995 | 0.300 |
Why?
| | Abdominal Pain | 3 | 2019 | 149 | 0.270 |
Why?
| | Drug Packaging | 2 | 2017 | 41 | 0.250 |
Why?
| | Marijuana Abuse | 2 | 2020 | 214 | 0.250 |
Why?
| | Alcohol Deterrents | 1 | 2025 | 26 | 0.220 |
Why?
| | Harm Reduction | 1 | 2026 | 49 | 0.220 |
Why?
| | Cross-Sectional Studies | 8 | 2021 | 5922 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2021 | 947 | 0.200 |
Why?
| | Academic Medical Centers | 2 | 2017 | 554 | 0.200 |
Why?
| | Vomiting | 3 | 2020 | 131 | 0.200 |
Why?
| | Capsaicin | 2 | 2020 | 30 | 0.190 |
Why?
| | Benzodiazepines | 3 | 2023 | 168 | 0.180 |
Why?
| | Prescription Drug Misuse | 1 | 2022 | 53 | 0.170 |
Why?
| | Aged | 10 | 2026 | 26215 | 0.170 |
Why?
| | Quality Indicators, Health Care | 1 | 2023 | 336 | 0.160 |
Why?
| | Inpatients | 1 | 2025 | 553 | 0.160 |
Why?
| | Young Adult | 8 | 2019 | 14251 | 0.150 |
Why?
| | Patient Handoff | 1 | 2020 | 44 | 0.150 |
Why?
| | Certification | 1 | 2020 | 119 | 0.150 |
Why?
| | Haloperidol | 1 | 2019 | 32 | 0.150 |
Why?
| | Antiemetics | 1 | 2019 | 51 | 0.140 |
Why?
| | Drug Storage | 2 | 2017 | 53 | 0.140 |
Why?
| | Ketorolac | 1 | 2019 | 33 | 0.140 |
Why?
| | Infection Control | 1 | 2020 | 173 | 0.140 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.140 |
Why?
| | Poisoning | 2 | 2017 | 119 | 0.140 |
Why?
| | Qualitative Research | 2 | 2024 | 1683 | 0.140 |
Why?
| | Automobile Driving | 1 | 2020 | 157 | 0.130 |
Why?
| | Acetaminophen | 2 | 2011 | 267 | 0.130 |
Why?
| | Risk Factors | 4 | 2023 | 10917 | 0.130 |
Why?
| | United States | 7 | 2021 | 16123 | 0.130 |
Why?
| | Quality Improvement | 2 | 2024 | 1296 | 0.130 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.130 |
Why?
| | Mass Screening | 1 | 2026 | 1361 | 0.130 |
Why?
| | Medical Staff, Hospital | 1 | 2017 | 80 | 0.120 |
Why?
| | Referral and Consultation | 2 | 2021 | 868 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2026 | 1102 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 346 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2019 | 249 | 0.120 |
Why?
| | Logistic Models | 3 | 2017 | 2139 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 24 | 0.120 |
Why?
| | Drug Utilization | 2 | 2014 | 168 | 0.120 |
Why?
| | Odds Ratio | 2 | 2017 | 1083 | 0.110 |
Why?
| | Codeine | 1 | 2015 | 7 | 0.110 |
Why?
| | Inappropriate Prescribing | 1 | 2016 | 66 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Hydrocodone | 1 | 2015 | 18 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 81 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1711 | 0.110 |
Why?
| | Medication Errors | 1 | 2015 | 85 | 0.110 |
Why?
| | Medication Reconciliation | 1 | 2015 | 32 | 0.110 |
Why?
| | Guideline Adherence | 2 | 2017 | 587 | 0.110 |
Why?
| | Oxycodone | 1 | 2015 | 52 | 0.110 |
Why?
| | Cohort Studies | 2 | 2016 | 6032 | 0.110 |
Why?
| | Self Report | 2 | 2020 | 876 | 0.100 |
Why?
| | Prospective Studies | 3 | 2023 | 8075 | 0.100 |
Why?
| | Urban Population | 1 | 2017 | 494 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 85 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 261 | 0.100 |
Why?
| | Antipsychotic Agents | 2 | 2019 | 211 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2016 | 326 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2021 | 1101 | 0.090 |
Why?
| | Chronic Pain | 1 | 2016 | 292 | 0.090 |
Why?
| | Adolescent | 6 | 2019 | 22573 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2014 | 463 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2019 | 8346 | 0.080 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.080 |
Why?
| | Colorado | 3 | 2019 | 4556 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 562 | 0.080 |
Why?
| | Fractures, Bone | 1 | 2015 | 428 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2010 | 139 | 0.070 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2011 | 128 | 0.070 |
Why?
| | Curriculum | 1 | 2016 | 1074 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1582 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 89 | 0.070 |
Why?
| | Cardiovascular System | 1 | 2009 | 139 | 0.070 |
Why?
| | Program Evaluation | 2 | 2026 | 944 | 0.060 |
Why?
| | Antidotes | 1 | 2009 | 145 | 0.060 |
Why?
| | Prescription Drug Overuse | 2 | 2017 | 10 | 0.060 |
Why?
| | Nausea | 2 | 2019 | 112 | 0.060 |
Why?
| | Medical History Taking | 2 | 2015 | 117 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2025 | 133 | 0.050 |
Why?
| | Nonprescription Drugs | 2 | 2015 | 69 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 21 | 0.050 |
Why?
| | Lorazepam | 1 | 2023 | 26 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3634 | 0.040 |
Why?
| | Organizational Innovation | 1 | 2020 | 119 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2024 | 916 | 0.040 |
Why?
| | Wisconsin | 1 | 2020 | 100 | 0.040 |
Why?
| | Administration, Topical | 1 | 2019 | 155 | 0.040 |
Why?
| | Data Collection | 1 | 2022 | 643 | 0.040 |
Why?
| | Community Health Workers | 1 | 2020 | 88 | 0.030 |
Why?
| | Syndrome | 1 | 2019 | 381 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 289 | 0.030 |
Why?
| | Risk Assessment | 2 | 2017 | 3752 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 297 | 0.030 |
Why?
| | Health Transition | 1 | 2016 | 8 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 528 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 195 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 6085 | 0.030 |
Why?
| | Plant Preparations | 1 | 2015 | 37 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 236 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 572 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 536 | 0.030 |
Why?
| | Analgesics | 1 | 2016 | 231 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2016 | 268 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 121 | 0.030 |
Why?
| | Vitamins | 1 | 2015 | 184 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 558 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2016 | 1300 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1547 | 0.020 |
Why?
| | Eating | 1 | 2014 | 387 | 0.020 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3416 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2015 | 584 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 419 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 42 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 197 | 0.020 |
Why?
| | Decision Making | 1 | 2017 | 982 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3346 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 26 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 18 | 0.020 |
Why?
| | Aripiprazole | 1 | 2009 | 20 | 0.020 |
Why?
| | Risperidone | 1 | 2009 | 30 | 0.020 |
Why?
| | Aging | 1 | 2020 | 1973 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 428 | 0.020 |
Why?
| | Anaphylaxis | 1 | 2010 | 102 | 0.020 |
Why?
| | Thiazoles | 1 | 2009 | 142 | 0.020 |
Why?
| | Safety | 1 | 2010 | 358 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1043 | 0.020 |
Why?
| | Child | 2 | 2017 | 22739 | 0.020 |
Why?
| | Quinolones | 1 | 2009 | 204 | 0.020 |
Why?
| | Piperazines | 1 | 2009 | 375 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2028 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 1269 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2009 | 740 | 0.010 |
Why?
| | Infant | 1 | 2017 | 10090 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 4329 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11868 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2010 | 11793 | 0.010 |
Why?
|
|
Hoppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|